文献速递心力衰竭与心肌病心律失常血脂与心血管预防

免疫检查点抑制剂治疗患者心脏事件风险的丹麦全国性研究

The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study.
PubMed 文献 · Eur Heart J · 2021-01-01

该研究纳入丹麦2011-17年全国肺癌和恶性黑色素瘤连续患者,评估免疫检查点抑制剂(ICI)治疗后的心脏事件风险。主要复合结局为心律失常、心包炎/心肌炎、心力衰竭或心血管死亡。结果显示ICI治疗患者心脏事件发生率升高,肺癌患者1年绝对风险为9.7%,黑色素瘤PD1i和CTLA-4i治疗者分别为6.6%和7.5%。

要点

  • 肺癌患者接受PD1i后1年心脏事件绝对风险为9.7%(95%CI 6.8-12.5)。
  • 黑色素瘤患者接受PD1i或CTLA-4i后1年风险分别为6.6%和7.5%。
  • ICI治疗后6个月内肺癌和黑色素瘤患者心脏事件风险显著增加。

核心结论

  • 在肺癌和恶性黑色素瘤患者中,接受ICI治疗者心脏事件发生率升高。
  • 本研究的绝对风险高于既往药物警戒研究(如1年心包炎/心肌炎风险1.8%)。

研究设计与样本

  • 全国性队列研究,纳入丹麦2011-17年连续肺癌或恶性黑色素瘤患者。
  • 主要复合结局为心脏事件(心律失常、心包炎/心肌炎、心力衰竭)或心血管死亡,采用多变量Cox模型分析。

主要发现

  • 肺癌PD1i治疗者1年心脏事件绝对风险为9.7%(95%CI 6.8-12.5)。
  • 黑色素瘤PD1i和CTLA-4i治疗者1年风险分别为6.6%(95%CI 1.8-11.3)和7.5%(95%CI 3.7-11.3)。
  • 首次ICI给药后6个月内,肺癌患者风险比(HR)为2.14(95%CI 1.50-3.05),黑色素瘤PD1i和CTLA-4i患者HR分别为4.30(95%CI 1.38-13.42)和4.93(95%CI 2.45-9.94)。
  • 6个月后,肺癌患者HR为2.26(95%CI 1.27-4.02),黑色素瘤CTLA-4i患者HR为3.48(95%CI 1.91-6.35)。

临床怎么用

  • 对接受ICI治疗的肺癌和黑色素瘤患者,应警惕心脏事件风险,尤其在治疗开始后6个月内。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The study aimed to estimate the risk of cardiac events in immune checkpoint inhibitor (ICI)-treated patients with lung cancer or malignant melanoma. METHODS AND RESULTS: The study included consecutive patients with lung cancer or malignant melanoma in 2011-17 nationwide in Denmark. The main composite outcome was cardiac events (arrhythmia, peri- or myocarditis, heart failure) or cardiovascular death. Absolute risks were estimated and the association of ICI and cardiac events was analysed in multivariable Cox models. We included 25 573 patients with lung cancer. Of these, 743 were treated with programmed cell death-1 inhibitor (PD1i) and their 1-year absolute risk of cardiac events was 9.7% [95% confidence interval (CI) 6.8-12.5]. Of the 13 568 patients with malignant melanoma, 145 had PD1i and 212 had cytotoxic T-lymphocyte-associated protein-4 inhibitor (CTLA-4i) treatment. Their 1-year risks were 6.6% (1.8-11.3) and 7.5% (3.7-11.3). The hazard rates of cardiac events were higher in patients with vs. without ICI treatment. Within 6 months from 1st ICI administration, the hazard ratios were 2.14 (95% CI 1.50-3.05) in patients with lung cancer and 4.30 (1.38-13.42) and 4.93 (2.45-9.94) in patients with malignant melanoma with PD1i and CTLA-4i, respectively. After 6 months, HRs were 2.26 (1.27-4.02) for patients with lung cancer and 3.48 (1.91-6.35) for patients with malignant melanoma and CTLA-4i. CONCLUSIONS: Among patients with lung cancer and malignant melanoma, ICI treated had increased rates of cardiac events. The absolute risks were higher in these data compared with previous pharmacovigilance studies (e.g. 1.8% peri-/myocarditis 1-year risk).

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. D'Souza M, Nielsen D, Svane IM, et al. The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study. Eur Heart J. 2021. PMID: 33291147. doi:10.1093/eurheartj/ehaa884

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。